Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer.
Future Oncol
; 15(10): 1115-1123, 2019 04.
Article
en En
| MEDLINE
| ID: mdl-30887825
ABSTRACT
AIM:
To evaluate activity of metronomic cyclophosphamide (mCTX) in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients. PATIENTS &METHODS:
We retrospectively evaluated a consecutive series of 74 mCRPC patients treated with at least one new agent after docetaxel failure, who received once-daily oral mCTX treatment at a fixed dose of 50 mg.RESULTS:
The treatment was well tolerated. Sixteen percent of the patients experienced a major biochemical response. Median progression-free survival was 4.0 months, and median overall survival was 8.1 months.CONCLUSIONS:
In the modern context of mCRPC, mCTX may represent a valuable and inexpensive alternative to new agents, which have shown similar activity in heavily pretreated patients.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Antineoplásicos Alquilantes
/
Ciclofosfamida
/
Neoplasias de la Próstata Resistentes a la Castración
Tipo de estudio:
Observational_studies
/
Prognostic_studies
Límite:
Aged
/
Aged80
/
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2019
Tipo del documento:
Article